Purple Biotech Ltd.
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PPBT research report →
Companypurple-biotech.com
Purple Biotech Ltd. , a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug for cancer patients in the United States. Its oncology pipeline includes CM24, a monoclonal antibody that blocks carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, which is in Phase 1b/2 clinical trials for the treatment of non-small cell lung cancer and pancreatic cancer; and NT219, a small molecule that targets insulin receptor substrate 1 and 2, and signal transducer and activator of transcription, which is in Phase 1/2 clinical trials for the treatment of recurrent and/or metastatic solid tumors and squamous cell carcinoma of the head and neck cancer.
- CEO
- Gil Efron
- IPO
- 2015
- Employees
- 9
- HQ
- Rehovot, IL
Price Chart
Valuation
- Market Cap
- $411.49K
- P/E
- -0.25
- P/S
- 0.00
- P/B
- 0.65
- EV/EBITDA
- 0.48
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -123.47%
- ROIC
- -302.45%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-26,386,000 · -264.45%
- EPS
- $-11080.00 · -24967.87%
- Op Income
- $-27,458,000
- FCF YoY
- 61.44%
Performance & Tape
- 52W High
- $29.00
- 52W Low
- $2.71
- 50D MA
- $4.13
- 200D MA
- $7.61
- Beta
- -0.57
- Avg Volume
- 13.56K
Get TickerSpark's AI analysis on PPBT
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Recent Insider Transactions
| Date | Insider | Type | Shares |
|---|---|---|---|
| Mar 18, 26 | Rock Simcha | other | 0 |
| Mar 18, 26 | Rock Simcha | other | 2,650,000 |
| Mar 18, 26 | Zilberberg Suzana | other | 0 |
| Mar 18, 26 | Zilberberg Suzana | other | 2,650,000 |
| Mar 18, 26 | Agmon Ido | other | 0 |
| Mar 18, 26 | Agmon Ido | other | 2,650,000 |
| Mar 18, 26 | Efron Gil | other | 0 |
| Mar 18, 26 | Efron Gil | other | 13,500,000 |
| Mar 18, 26 | Schickler Michael | other | 0 |
| Mar 18, 26 | Schickler Michael | other | 7,100,000 |
Our PPBT Coverage
We haven't published any research on PPBT yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate PPBT Report →